Microvascular Therapeutics
Dr. Rosenberg is a graduate of Temple University School of Medicine and trained in general surgery at Albert Einstein Medical Center in Philadelphia. He joined Squibb Diagnostics in 1990 and worked on the clinical development and approval of two novel oral contrast agents from ImarX pharmaceuticals: SonoRx and LumenHance. In 1996, he was hired by Bristol-Myers Squibb Medical Imaging, formerly DuPont Pharma, to develop the ultrasound contrast agent Definity (DMP-115), also invented by Imarx pharmaceuticals. Dr. Rosenberg is currently working for Bayer Radiology where he led the initial approval and additional indications for Gadavist in the US.
This person is not in the org chart
This person is not in any offices
Microvascular Therapeutics
Microvascular Therapeutics (MVT) is a biotechnology company specializing in the development of microbubble and nanotechnology products for the diagnosis and treatment of disease.